Innovative drugs granted conditional market approval

STO-REC-STAT2VV0A9T1 Official
11

China · 2024

Innovative drugs granted conditional market approval in China stood at 11 in 2024 (NMPA).

Original source
Publisher
NMPA
Authority tier
T1 Official
Locator
Measures facilitate approval of 48 first-in-class innovative drugs
Retrieved
17 Sep 2026
Status
Verified

What the source says

Among them, 17 received market approval through a priority review pathway, 11 gained conditional market approval and 13 were included in breakthrough therapy programs during clinical trials, according to the report from the administration's drug evaluation center.

Verbatim extraction verified: The figure 11 is directly attested in the quoted passage (Measures facilitate approval of 48 first-in-class innovative drugs).

The figure above was extracted from this passage. If it does not match, the extraction is wrong and we want to know.

Cite this figure

Published under CC BY 4.0. Attribute the original publisher; the citations below do that for you and link to this permanent record.

APA
National Medical Products Administration. (2024). Measures facilitate approval of 48 first-in-class innovative drugs. Retrieved September 17, 2026, from https://english.nmpa.gov.cn/2025-03/21/c_1080286.htm. Via StatOrigin, https://statorigin.org/stat/stat_2VV0A98K89ACW40MG9XWRJ02NZ
MLA
National Medical Products Administration. "Measures facilitate approval of 48 first-in-class innovative drugs." 2024, https://english.nmpa.gov.cn/2025-03/21/c_1080286.htm. Accessed 17 Sept. 2026 via StatOrigin, https://statorigin.org/stat/stat_2VV0A98K89ACW40MG9XWRJ02NZ.
Chicago
National Medical Products Administration. "Measures facilitate approval of 48 first-in-class innovative drugs." 2024. https://english.nmpa.gov.cn/2025-03/21/c_1080286.htm. Accessed September 17, 2026. Cited from StatOrigin, https://statorigin.org/stat/stat_2VV0A98K89ACW40MG9XWRJ02NZ.
BibTeX
@misc{nmpa2024innovativerj02nz, author = {{National Medical Products Administration}}, title = {Measures facilitate approval of 48 first-in-class innovative drugs}, year = {2024}, howpublished = {StatOrigin, https://statorigin.org}, url = {https://statorigin.org/stat/stat_2VV0A98K89ACW40MG9XWRJ02NZ}, note = {Original source: https://english.nmpa.gov.cn/2025-03/21/c\_1080286.htm. Accessed September 17, 2026.} }

Provenance and verification

Everything needed to check this number yourself, without taking our word for it.

Chain of Custody · Verification Audit
Record: STO-REC-STAT2VV0A9 T1 Official

Primary Source

Publisher
National Medical Products Administration · homepage ↗
Authority tier
Tier 1 · Multilateral Official
Report
Measures facilitate approval of 48 first-in-class innovative drugs
Type
Press release
Published
Locator
Measures facilitate approval of 48 first-in-class innovative drugs
Retrieved
17 September 2026
Link status
Reachable (HTTP 200)
Report licence
See source

Verification & Integrity

Audit status
Verified
Review protocol
Editorial review
Checked on
17 September 2026
Last revision
17 September 2026
Archival URI
/stat/stat_2VV0A98K89ACW40MG9XWRJ02NZ